[1]
|
程月, 金海燕. 免疫检查点抑制剂相关性肝损伤的研究进展[J]. 延边大学医学学报, 2023, 46(4): 338-340. https://doi.org/10.16068/j.1000-1824.2023.04.027
|
[2]
|
华雨薇, 赵林. 免疫治疗相关肝毒性的诊断与管理[J]. 协和医学杂志, 2021, 12(5): 798-806. https://doi.org/10.12290/xhyxzz.2021-0138
|
[3]
|
Regev, A., Avigan, M.I., Kiazand, A., et al. (2020) Best Practices for Detection, Assessment and Management of Suspected Immune-Mediated Liver Injury Caused by Immune Checkpoint Inhibitors during Drug Development. Journal of Autoimmunity, 114, Article 102514. https://doi.org/10.1016/j.jaut.2020.102514
|
[4]
|
Robert, C., Thomas, L., Bondarenko, I., et al. (2011) Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. The New England Journal of Medicine, 364, 2517-2526. https://doi.org/10.1056/NEJMoa1104621
|
[5]
|
Hammers, H.J., Plimack, E.R., Infante, J.R., et al. (2017) Safety and Efficacy of Nivolumab in Combination with Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. Journal of Clinical Oncology, 35, 3851-3858. https://doi.org/10.1200/JCO.2016.72.1985
|
[6]
|
Pollack, M.H., Betof, A., Dearden, H., et al. (2018) Safety of Resuming Anti-PD-1 in Patients with Immune-Related Adverse Events (irAEs) during Combined Anti-CTLA-4 and Anti-PD1 in Metastatic Melanoma. Annals of Oncology, 29, 250-255. https://doi.org/10.1093/annonc/mdx642
|
[7]
|
De Martin, E., Michot, J.-M., Rosmorduc, O., et al. (2020) Liver Toxicity as a Limiting Factor to the Increasing Use of Immune Checkpoint Inhibitors. JHEP Reports: Innovation in Hepatology, 2, Article 100170. https://doi.org/10.1016/j.jhepr.2020.100170
|
[8]
|
Brown, Z.J., Heinrich, B., Steinberg, S.M., et al. (2017) Safety in Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors as Compared to Melanoma and Non-Small Cell Lung Cancer. Journal for Immunotherapy of Cancer, 5, 93. https://doi.org/10.1186/s40425-017-0298-2
|
[9]
|
Fife, B.T. and Bluestone, J.A. (2008) Control of Peripheral T-Cell Tolerance and Autoimmunity via the CTLA-4 and PD-1 Pathways. Immunological Reviews, 224, 166-182. https://doi.org/10.1111/j.1600-065X.2008.00662.x
|
[10]
|
Esfahani, K., Meti, N., Miller, W.H., et al. (2019) Adverse Events Associated with Immune Checkpoint Inhibitor Treatment for Cancer. CMAJ: Canadian Medical Association Journal, 191, E40-E46. https://doi.org/10.1503/cmaj.180870
|
[11]
|
Celsa, C., Cabibbo, G., Fulgenzi, C.A.M., et al. (2023) Characteristics and Outcomes of Immunotherapy-Related Liver Injury in Patients with Hepatocellular Carcinoma versus Other Advanced Solid Tumours. Journal of Hepatology, 80, 431-442. https://doi.org/10.1016/j.jhep.2023.10.040
|
[12]
|
Ramos-Casals, M., Brahmer, J.R., Callahan, M.K., et al. (2020) Immune-Related Adverse Events of Checkpoint Inhibitors. Nature Reviews Disease Primers, 6, Article No. 38. https://doi.org/10.1038/s41572-020-0160-6
|
[13]
|
Das, R., Bar, N., Ferreira, M., et al. (2018) Early B Cell Changes Predict Autoimmunity Following Combination Immune Checkpoint Blockade. The Journal of Clinical Investigation, 128, 715-720.
|
[14]
|
Peeraphatdit, T.B., Wang, J., Odenwald, M.A., et al. (2020) Hepatotoxicity from Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation. Hepatology, 72, 315-329. https://doi.org/10.1002/hep.31227
|
[15]
|
Eun, Y., Kim, I.Y., Sun, J.-M., et al. (2019) Risk Factors for Immune-Related Adverse Events Associated with Anti-PD-1 Pembrolizumab. Scientific Reports, 9, Article 14039. https://doi.org/10.1038/s41598-019-50574-6
|
[16]
|
Takinami, M., Ono, A., Kawabata, T., et al. (2021) Comparison of Clinical Features between Immune-Related Sclerosing Cholangitis and Hepatitis. Investigational New Drugs, 39, 1716-1723. https://doi.org/10.1007/s10637-021-01136-z
|
[17]
|
曾燕霖, 李媛, 唐颢, 等. 免疫检查点抑制剂导致免疫介导性肝损伤患者的临床和病理特征分析[J]. 中华内科杂志, 2023, 62(6): 700-704. https://doi.org/10.3760/cma.j.cn112138-20220517-00379
|
[18]
|
Vani, V., Regge, D., Cappello, G., et al. (2020) Imaging of Adverse Events Related to Checkpoint Inhibitor Therapy. Diagnostics, 10, Article 216. https://doi.org/10.3390/diagnostics10040216
|
[19]
|
Haanen, J.B.A.G., Carbonnel, F., Robert, C., et al. (2017) Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 28, IV119-IV142. https://doi.org/10.1093/annonc/mdx225
|
[20]
|
Cheung, V., Gupta, T., Payne, M., et al. (2019) Immunotherapy-Related Hepatitis: Real-World Experience from a Tertiary Centre. Frontline Gastroenterology, 10, 364-371. https://doi.org/10.1136/flgastro-2018-101146
|
[21]
|
Schneider, B.J., Naidoo, J., Santomasso, B.D., et al. (2021) Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology, 39, 4073-4126. https://doi.org/10.1200/JCO.21.01440
|
[22]
|
牛志成, 王雷, 汪治宇. 免疫检查点抑制剂相关不良反应的管理专家共识[J]. 河北医科大学学报, 2021, 42(3): 249-255.
|
[23]
|
Li, M., Wong, D., Vogel, A.S., et al. (2022) Effect of Corticosteroid Dosing on Outcomes in High-Grade Immune Checkpoint Inhibitor Hepatitis. Hepatology, 75, 531-540. https://doi.org/10.1002/hep.32215
|
[24]
|
Ziemer, M., Koukoulioti, E., Beyer, S., et al. (2017) Managing Immune Checkpoint-Inhibitor-Induced Severe Autoimmune-Like Hepatitis by Liver-Directed Topical Steroids. Journal of Hepatology, 66, 657-659. https://doi.org/10.1016/j.jhep.2016.11.015
|
[25]
|
Gauci, M.-L., Baroudjian, B., Zeboulon, C., et al. (2018) Immune-Related Hepatitis with Immunotherapy: Are Corticosteroids Always Needed? Journal of Hepatology, 69, 548-550. https://doi.org/10.1016/j.jhep.2018.03.034
|